Permeability of the blood-tumor barrier is enhanced by combining vascular endothelial growth factor with papaverine

Journal of Neuroscience Research

Volumn 92, Issue 6, 2014, Pages 703-713

  Yang, Zhi hang ^a   Liu, Li bo ^a   Zhao, Li ni ^a   Liu, Yun hui ^a   Xue, Yi xue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Blood tumor barrier; Papaverine; Pinocytotic vesicle; Tight junctions; Vascular endothelial growth factor

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; CLAUDIN 5; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; EVANS BLUE; HEXAMETHONIUM BROMIDE; I KAPPA B; OCCLUDIN; PAPAVERINE; VASCULOTROPIN; PHOSPHODIESTERASE INHIBITOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TUMOR BARRIER; BLOOD VESSEL PERMEABILITY; CAVEOLA; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAVASATION; FEMALE; IMMUNOHISTOCHEMISTRY; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PERMEABILITY BARRIER; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RAT; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; ANIMAL; BRAIN TUMOR; CAPILLARY PERMEABILITY; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GLIOMA; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE; VASCULARIZATION; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS, EXPERIMENTAL; PAPAVERINE; PHOSPHODIESTERASE INHIBITORS; PINOCYTOSIS; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897576094     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23348     Document Type: Article

References (52)

1. Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, et al. 2010. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 5:e8727.
2. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. 1999. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463-23467.
3. Aslam M, Ahmad N, Srivastava R, Hemmer B. 2012. TNF-alpha induced NFκB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 57:269-275.
4. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, et al. 2004. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 28:243-248.
5. Chini B, Parenti M. 2004. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 32:325-338.
6. Davies DC. 2002. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200:639-646.
7. Dobrogowska DH, Lossinsky AS, Tarnawski M, Vorbrodt AW. 1998. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 27:163-173.
8. Drab M, Verkade P, Elger M, Kasper M, Lohn M, et al. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293:2449-2452.
9. Dvorak AM, Feng D. 2001. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem 49:419-432.
10. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1926-1939.
11. Dye JF, Leach L, Clark P, Firth JA. 2001. Cyclic AMP and acidic fibroblast growth factor have opposing effects on tight and adherens junctions in microvascular endothelial cells in vitro. Microvasc Res 62:94-113.
12. Faehling M, Kroll J, Föhr KJ, Fellbrich G, Mayr U, et al. 2002. Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole. FASEB J 16:1805-1807.
13. Fischer S, Wobben M, Marti HH, Renz D, Schaper W. 2002. Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 63:70-80.
14. Folkman J. 1995. Seminars in medicine of the beth israel hospital, boston: clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
15. Fontijn RD, Volger OL, Fledderus JO, Reijerkerk A, de Vries HE, et al. 2008. SOX-18 controls endothelial-specific claudin-5 gene expression and barrier function. Am J Physiol Heart Circ Physiol 294:H891-H900.
16. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, et al. 1993. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123:1777-1788.
17. Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, et al. 1994. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 127:1617-1626.
18. Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, et al. 2001. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Rev 36:258-264.
19. Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, et al. 1997. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 110:1603-1613.
20. Huang J, Siragy HM. 2012. Sodium depletion enhances renal expression of (pro)renin receptor via cyclic GMP-protein kinase G signaling pathway. Hypertension 59:317-323.
21. Ishizaki T, Chiba H, Kojima T, Fujibe M, Soma T. 2003. Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and -independent pathways. Exp Cell Res 290:275-288.
22. Kevil CG, Payne DK, Mire E, Alexander JS. 1998. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273:15099-15103.
23. Komarova Y, Malik AB. 2010. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 72:463-493.
24. Kuribayashi M, Wang J, Fujiwara O, Doi Y, Nabae K, et al. 2005. Lack of effects of 1439 MHz electromagnetic near field exposure on the blood-brain barrier in immature and young rats. Bioelectromagnetics 26:578-588.
25. Lajoie P, Nabi IR. 2007. Regulation of raft-dependent endocytosis. J Cell Mol Med 11:644-653.
26. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, et al. 2009. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6:1017-1032.
27. Liu XD, Chen HB, Tong Q, Li XY, Zhu MJ, et al. 2011. Molecular characterization of caveolin-1 in pigs infected with Haemophilus parasuis. J Immunol 186:3031-3046.
28. Louis DN. 2006. Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97-117.
29. Lund CV, Nguyen MT, Owens GC, Pakchoian AJ, Shaterian A, et al. 2006. Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78:19-29.
30. Mayhan WG. 1999. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol 276:C1148-C1153.
31. Miyake JA, Benadiba M, Colquhoun A. 2009. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis 8:8.
32. Nicolau M, Sirois MG, Bui M, Plante GE, Sirois P, et al. 1993. Plasma extravasation induced by neurokinins in conscious rats: receptor characterization with agonists and antagonists. Can J Physiol Pharmacol 71:217-221.
33. Ningaraj NS, Rao MK, Black KL. 2003. Adenosine 5-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res 63:8899-8911.
34. Poch G, KuKovetz WR. 1971. Papaverine-induced inhibition of phosphodiesterase activity in various mammalian tissues. Life Sci 10:133-144.
35. Polson JB, Krzanowski JJ, Fitzpatrick DF, Szentivanyi A. 1978. Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle. Biochem Pharmacol 27:254-256.
36. Portugal CC, da Encarnação TG, Socodato R, Moreira SR, Brudzewsky D, et al. 2012. Nitric oxide modulates sodium vitamin C transporter 2 (SVCT-2) protein expression via protein kinase G (PKG) and nuclear factor-κB (NF-κB). J Biol Chem 287:3860-3872.
37. Roseberry AG, Hosey MM. 2001. Internalization of the M2 muscarinic acetylcholine receptor proceeds through an atypical pathway in HEK293 cells that is independent of clathrin and caveolae. J Cell Sci 114:739-746.
38. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, et al. 1993. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metast Rev 12:303-324.
39. Siednienko J, Nowak J, Moynagh PN, Gorczyca WA. 2011. Nitric oxide affects IL-6 expression in human peripheral blood mononuclear cells involving cGMP-dependent modulation of NF-κB activity. Cytokine 54:282-288.
40. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. 1987. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 67:697-705.
41. Sugita M, Black KL. 1998. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res 58:914-920.
42. Takashi K, Susumu I, Shinoda H, Inoue M, et al. 2007. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170:1389-1397.
43. Tiruppathi C, Shimizu J, Miyawaki-Shimizu K, Vogel SM, Bair AM, et al. 2008. Role of NF-kappaB-dependent caveolin-1 expression in the mechanism of increased endothelial permeability induced by lipopolysaccharide. J Biol Chem 283:4210-4218.
44. Van Helmond ZK, Miners JS, Bednall E, Chalmers KA, Zhang Y, et al. 2007. Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol 33:317-327.
45. Wang JE, Liu YH, Liu LB, Xia CY, Zhang Z, et al. 2011. Effects of combining low frequency ultrasound irradiation with papaverine on the permeability of the blood-tumor barrier. J Neurooncol 102:213-224.
46. Werther K, Christensen IJ, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group. 2002. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417-423.
47. Wolburg H, Lippoldt A. 2002. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323-337.
48. Xue H, Wang H, Kong L, Zhou H. 1998. Opening blood-brain barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma. Chin Med J (Engl) 111:751-753.
49. Yuan SY. 2002. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 39:213-223.
50. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K. 2000. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838.
51. Zhao LN, Yang ZH, Liu YH, Ying HQ, Zhang H, et al. 2011. Vascular endothelial growth factor increases permeability of the blood-tumor barrier via caveolae-mediated transcellular pathway. J Mol Neurosci 44:122-129.
52. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, et al. 2002. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 99:11375-11380.